Amyloid-β assessed by florbetapir F 18 PET and 18-month cognitive decline

P. Murali Doraiswamy(Alzheimer’s Disease Neuroimaging Initiative), Reisa A. Sperling(Harvard University), Richard Holub(Meridien Research), Crystal Flynn Longmire(Medical University of South Carolina), Michael Grundman(University of San Diego), Carl Sadowsky(Nova Southeastern University), Ron Korn(Alzheimer's Association), Danna Jennings, Mat D. Davis(Clinical Research Institute), Daniel Skovronsky(Eli Lilly (United States)), Eric M. Reiman(Alzheimer's Association), Robert E. Coleman(University of Sheffield), Jeff D. Williamson(University Memory and Aging Center), Adam Fleisher(Banner Alzheimer’s Institute), Michael J. Pontecorvo(Eli Lilly (United States)), Michael D. Devous, Beth Safirstein(Velocity Clinical Research (United States)), Karel D. Kovnat(Wake Forest University), Mark A. Mintun(Washington University in St. Louis), Gustavo Alva(Medical University of South Carolina), George Jewell(Massachusetts General Hospital), Jeanette Wendt(Johns Hopkins University), Ranjan Duara(Alzheimer’s Disease Neuroimaging Initiative), Cynthia Murphy(The Memory Clinic), Keith A. Johnson(Brigham and Women's Hospital), Christopher M. Clark(Institute on Aging), Marwan N. Sabbagh(Cleveland Clinic), Michael W. Weiner(San Francisco VA Medical Center), Mildred V. Farmer(Meridien Research), Geoffrey L. Ahern(University of Arizona), Alan Carpenter, Dean F. Wong(University of Maryland, Baltimore), Abhinay D. Joshi
Neurology
July 12, 2012
Cited by 228


Related Papers